Apogee Therapeutics, Inc. Common Stock (APGE) Financials
Key financial figures for Apogee Therapeutics, Inc. Common Stock (Q2 2026).
Apogee reported a wider Q2 2026 net loss of $85.9 million as R&D spending scaled ahead of planned Phase 3 zumilokibart trials, with the quarter now overshadowed by AbbVie's pending $135.11-per-share, $10.9 billion all-cash acquisition expected to close in Q3 2026. Net loss widened to $85.9M in Q2 2026 from $66.1M in Q2 2025, driven by higher R&D and G&A spend and $4.4M of merger-related transaction costs tied to the AbbVie deal. R&D expense rose to $67.3M (from $55.7M a year ago) on continued zumilokibart development and team growth; G&A rose to $24.3M (from $17.5M) on higher headcount and equity compensation. Figures are for Q2 2026, as Apogee Therapeutics reported them.
- Revenue
- $0
- Net Income
- -$86M
- EPS
- $-1.14
- Total Assets
- $1.3B
- Operating Cash Flow
- -$71M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$86M | -$1.14 | -$71M | |
| Q1 FY2026 | $0 | -$74M | -$1.06 | -$56M | |
| Q4 FY2025 | $0 | -$69M | -$1.03 | -$63M | |
| Q3 FY2025 | $0 | -$65M | -$1.11 | -$54M | |
| Q2 FY2025 | $0 | -$66M | -$1.13 | -$63M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$256M | -$4.22 | -$233M | |
| FY2024 | $0 | -$182M | -$3.30 | -$172M | |
| FY2023 | $0 | -$84M | -$1.66 | -$75M |
Frequently asked questions
What was Apogee Therapeutics's revenue last quarter?
Apogee Therapeutics reported revenue of $0.00 for Q2 FY2026.
Is Apogee Therapeutics profitable?
Not in its most recent reported period. Apogee Therapeutics reported a net loss of $85.9 million for Q2 FY2026.
How much free cash flow did Apogee Therapeutics generate?
Apogee Therapeutics generated free cash flow of -$71.4 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Apogee Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.